OJOluwole Jegede

Oluwole Jegede

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oluwole Jegede has a total of 178 co-authors. Here are the top co-authors by number of shared publications:

  • Ayodeji Jolayemi

    Department of Psychiatry, Interfaith Medical Center, Brooklyn, NY, USA

    8 shared publications
  • Tolu Olupona

    Interfaith Medical Center

    6 shared publications
  • Chiedozie Ojimba

    Department of Psychiatry, Interfaith Medical Center, Brooklyn, NY, 11213, USA

    4 shared publications
  • Kodjovi Kodjo

    Department of Psychiatry, Interfaith Medical Center, Brooklyn, New York, USA

    4 shared publications
  • Robert A. Rosenheck

    Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA

    4 shared publications
  • Alexa Kahn

    American University of Antigua College of Medicine, Department of Psychiatry, Interfaith Medical Center, Brooklyn, New York, USA

    3 shared publications

Latest Publications

  • Open Access

    Rationale, design and methods of the Cul-CM study: a protocol for cultural adaptation of contingency management in adults with stimulant use disorder

    by Oluwole O Jegede, Sara J Becker, Theddeus Iheanacho, Chyrell Bellamy, Ismene Petrakis, Brian Kiluk, Carla Rash

    Introduction: Stimulant use disorder is a growing contributor to drug poisoning and mortality in the USA, with disproportionate impact on black communities driven by stimulant-opioid polysubstance use and other structural barriers to treatment. Contingency management (CM) is the most effective evidence-based treatment for stimulant use disorder but remains poorly implemented especially in minoritised communities. Cultural adaptation represents a promising implementation strategy to improve acceptability, engagement and equity of CM while maintaining fidelity to core evidence-based programming. Methods and analysis: The Cultural Adaptation of Contingency Management ( Cul-CM ) study is a multiphase, mixed-methods study designed to culturally adapt CM for black adults with stimulant use disorder and evaluate its preliminary outcomes in a pilot randomised controlled trial (RCT), guided by the PEN-3 cultural model and the ADAPT-ITT framework. Phase I consists of an assessment of clinician beliefs about CM implementation using the Extended Contingency Management Beliefs Questionnaire (CMBQ-CA+, with an exploratory Cultural Adaptation subscale) and a scoping review of CM adaptation for substance use disorder. Phase II employs PEN-3-informed individual interviews and focus groups to identify culturally salient determinants of CM uptake and engagement. Findings from Phases I and II, in addition to iterative expert and community advisory board reviews and feedback, will inform the development of a culturally adapted CM (CACM) protocol, which retains core effectiveness elements and modifies peripheral delivery elements of CM. Finally, the Phase III consists of a three-arm pilot RCT (n=60) comparing the CACM, standard CM and treatment as usual following a 1 week lead-in (priming) phase. Primary outcomes include stimulant abstinence and longest duration of continuous abstinence. Secondary outcomes include treatment acceptability, satisfaction, feasibility and retention. Cul-CM operationalises cultural adaptation as a systematic, theory-driven strategy to improve CM outcomes in adults with stimulant use disorder and promote equitable uptake in community treatment settings. Cul-CM represents a replicable framework for culturally adapting CM to ensure equitable access, engagement and improve outcomes. Ethics and dissemination: Ethical approval was obtained from the Yale University Institutional Review Board. All participants will provide written informed consent. Study findings will be disseminated through peer-reviewed publications, scientific conferences and community-engaged channels to inform culturally responsive approaches to CM for stimulant use disorder. Trial registration number: NCT07443332 .

  • Contingency Management for Stimulant-Opioid Co-Use: A Systematic Review and Meta-Analysis

    by Oluwole O. Jegede, Henrique N.P. Oliva, Tiago P. Prudente, Carla J. Rash, Srinivas B. Muvvala, Gustavo A. Md Angarita

    Objective: We conducted a meta-analysis (PROSPERO CRD420251000204) examining treatment outcomes associated with contingency management for individuals with stimulant-opioid co-use. Methods: We searched Cochrane Library, Embase, PubMed, PsycINFO, and Web of Science through March 2026. Randomized controlled trials evaluating contingency management among individuals with past-year stimulant-opioid co-use were eligible. Outcomes included the longest duration of continuous, simultaneous abstinence from stimulants and opioids during treatment, the percentage of combined stimulant-opioid–negative urine toxicology samples, and treatment retention. Data were extracted following PRISMA guidelines, and random-effects meta-analyses were performed. Results: Twenty-six trials (N=2356) were included. Across studies, cocaine was the stimulant of interest and heroin the primary opioid; fentanyl exposure was not reported in any trial. Contingency management significantly increased the longest duration of continuous abstinence from concurrent stimulant and opioid use compared with control conditions (mean difference=1.42 wk, 95% CI: 0.77–2.08; I ²=50%). Participants receiving contingency management were more likely to submit combined stimulant-opioid–negative urine samples (odds ratio=2.46, 95% CI: 1.96–3.10; I 2 =0%). Overall treatment retention did not differ between groups, though subgroup analyses suggested improved retention among participants not receiving medication for opioid use disorder. Conclusions: Contingency management improves abstinence outcomes among individuals with stimulant-opioid co-use across treatment settings. The absence of fentanyl-specific data highlights an urgent need for research addressing treatment strategies in the context of the evolving synthetic opioid epidemic.

  • Open Access

    Substance use disorders among young adults in North-Western Nigeria: descriptive survey of patterns of use

    by Charles Marke, Oluwole Jegede, Hesham Mukhtar, Abigail Ojo, Yusuf Boman, Bashir Yakasai, Charles Dike

    Background: Substance use disorder (SUD) is a rapidly growing public health challenge in developing countries across socioeconomic divides. In sub-Saharan Africa, the situation of SUD is particularly concerning and largely unexplored, with projections indicating a worsening trend. Aims: This study seeks to fill the gap by generating insights into the multifaceted nature of alcohol and drug use disorders among a young adult population in Nigeria. Method: This is a cross-sectional survey of 192 current students at a university of a metropolitan city in North-Western Nigeria, using the NIDA-Modified ASSIST version 2.0, adapted from the Alcohol, Smoking and Substance Involvement Screening Test. Results: About half of the participants (49.7%) were heavy drinkers, 36.5% and 56.8% reported past year tobacco smoking and use of prescription drugs for non-medical reasons, but only 7.4% had used illegal drugs daily in the past year. Cannabis and sedatives were the most used substances in the lifetime (56.2% and 47.9%, respectively) and past 3 months (52.4% and 51.1%, respectively). Men had greater odds of substance use in their lifetime (odds ratio 4.167, 95% CI 1.61–10.77; d.f. = 1, P = 0.003) and past three months (odds ratio 6.059, 95% CI 2.20–16.69; d.f. = 1, P ≤ 0.001), compared with women. Conclusions: The burden of SUD remains a major public health concern in Nigeria despite existing legislation, regulations and policies in the country. There is an urgent need improve diagnostic, treatment and preventative resources by engaging a massive public health campaign to alert the public of the dangers of SUD.

  • Open Access

    Clinical outcomes from a mid-western opioid treatment program during covid-19 emergency regulations: a brief report on the effect of tetrahydrocannabinol (THC) use on take home methadone access

    by Erin T. LaCourt, Oranu Ibekie, Charles C. Dike, Oluwole Jegede

    The study examines whether tetrahydrocannabinol (THC) use alone affected sustainability of weekly take-home methadone medication among a small sample of 33

  • Open Access

    A Preliminary Investigation of Brain Cannabinoid Receptor Type 1 (CB1R) Availability in Men with Opioid Use Disorder

    by Anahita Bassir Nia, Ardavan Mohammad Aghaei, Jeremy Weleff, Julia Shi, Angelina Contreras, Mackenzie Griffin, Oluwole Jegede, Brian Pittman, Ilan Harpaz-Rotem, Ansel Hillmer, et al.

    The endocannabinoid (eCB) system has been proposed as a potential target for developing new medications for opioid use disorder (OUD). However, the status of the eCB system, specifically brain cannabinoid receptor type 1 (CB1R) in OUD, is unknown. In this study, CB1R availability was measured in males with OUD on stable opioid agonist treatment (OAT) (n = 10) versus healthy controls (HC) (n = 18), using High-Resolution Research Tomography (HRRT) and the CB1R-specific radiotracer, [ 11 C]OMAR. The average volume of distribution ( V T ) across 13 regions was compared between the OUD and HC groups. Average V T was 15% lower in OUD vs. HC subjects (p = 0.04). Lower V T in OUD compared to HC was also observed in several corticolimbic areas. Within OUD no effects on CB1R availability were observed for treatment medication (methadone vs. buprenorphine), current stress levels, or antidepressant medication. No associations between the average V T and duration of OAT treatment or time since the last illicit opioid use were observed. This preliminary study suggests lower CB1R availability in men with OUD. Larger studies are necessary to replicate these findings. Future research should also draw from a more heterogeneous population, particularly by incorporating females, to better assess the potential confounding and moderating clinical factors. If confirmed, the observed alterations in CB1R availability in OUD may provide a rationale for targeting the eCB system in the treatment of OUD.

  • Open Access

    Governance for Anti-Racist AI in Healthcare: Integrating Racism-Related Stress in Psychiatric Algorithms for Black Americans

    by Christopher Fields, Carmen Black, Jannat K. Thind, Oluwole Jegede, Damla Aksen, Matthew Rosenblatt, Shervin Assari, Chyrell Bellamy, Elijah Anderson, Avram J Holmes, et al.

    While the world is aware of America’s history of enslavement, the ongoing impact of anti-Black racism in the United States remains underemphasized in health intervention modeling. In this Perspective, we argue that algorithmic bias—manifested in the worsened performance of clinical algorithms for Black versus white patients—is significantly driven by the failure to model the cumulative impacts of racism-related stress, particularly racial heteroscedasticity. We assert that current approaches to developing, implementing, and regulating AI in healthcare are insufficient to address the complex ways in which racism influences health outcomes. Accurately capturing these dynamics, and specifically accounting for the pervasive effects of racism on health, is essential for improving racial parity in clinical algorithm performance. Using psychiatric models as a conceptual framework, we outline key principles for anti-racist AI governance in healthcare, including: 1) mandating the inclusion of Black researchers and community members in AI development; 2) implementing rigorous audits to assess anti-Black bias; 3) requiring transparency in how algorithms process race-related data; and 4) establishing accountability measures that prioritize equitable outcomes for Black patients. By integrating these principles into healthcare AI governance, we can develop more equitable and culturally responsive interventions across medical specialties. This anti-racist approach challenges policymakers, researchers, clinicians, and AI developers to fundamentally rethink how AI is created, used, and regulated in healthcare, with profound implications for health policy, clinical practice, and patient outcomes across all medical domains.


  • The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review

    by Oluwole Jegede, Joao P. De Aquino, Connie Hsaio, Ebony Caldwell, Melissa C. Funaro, Ismene Petrakis, Srinivas B. Muvvala

    Background: The clinical implications of high potency synthetic opioids (HPSO) on medications for opioid use disorder (MOUDs) are not well understood. Although pharmacological interactions are plausible, the clinical significance of such interaction has not been systematically elucidated. This scoping review investigates the relationship between HPSO exposure and various MOUD treatment outcomes. Methods: We followed PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews) for scoping reviews with extensive a priori search strategy of databases: MEDLINE, EMBASE, PsycINFO, Web of Science, CINAHL, and Cochrane. Results: From 9149 studies, 34 fulfilled the inclusion criteria. Synthesized data reveal several critical insights: First, there is a variable but high occurrence (38%–80%) of HPSO usage among individuals with MOUDs. Second, MOUDs are linked to a decreased risk of overdoses and deaths associated with HPSO. Third, HPSO consumption is correlated with the risk of precipitated withdrawal when starting buprenorphine. Fourth, low-dose buprenorphine is being recognized as one method to avoid moderate withdrawal symptoms prior to treatment. Lastly, significant gaps exist in human experimental data concerning the effects of HPSO on key factors critical for treating OUD-craving, withdrawal symptoms, and pain. Conclusions: Current evidence supports MOUD safety and effectiveness in reducing nonmedical opioid use. Further research is needed to explore HPSO’s influence on the acute factors preceding nonmedical opioid use, such as cravings, withdrawal symptoms, and pain. This research could inform the optimization of MOUD dosing strategies. Achieving consensus and harmonizing data across clinical and research protocols could diminish variability, enhancing our understanding of HPSOs effect on MOUD treatment outcomes.


  • Open Access

    Investigating the association between multiple substance Use and dating violence involvement among U.S adolescents

    by Christian A. Nwabueze, Stanley Nkemjika, Obiamaka P. Okereke, Olasumbo E. Fagbenle, Abimbola E. Arisoyin, Chidalu Ibeneme, Colvette Brown, Joseph Ikekwere, Jacky S. Petion, Oluwaseun Oke, et al.


  • Monotonic Association of Increasing Past-Year Substance Use Disorder across a Four-Level Trauma Post-Traumatic Stress Disorder (PTSD) Hierarchy in a Nationwide Sample

    by Oluwole Jegede, Ajay Manhapra, Bin Zhou, Taeho Greg Rhee, Robert A. Rosenheck

    Objective: There is limited information on the differences in the association of substance use disorders (SUD) with four clinically relevant hierarchical groups based on trauma exposure and its consequences (1-no trauma; 2-trauma but no PTSD; 3-remitted PTSD; and 4-current PTSD). Methods: Among adults enrolled in a large nationally representative survey, the National Epidemiologic Survey on Alcohol and Related Conditions Wave III (NESARC III), we compared differences in SUD prevalence between each of the hierarchical trauma group and the prior group adjusting for potentially confounding factors. Results: Unadjusted results show that each increase in the hierarchy was associated with a greater likelihood of SUD diagnoses, even after adjusting for potentially confounding variables. However, after adjusting for covariates, comparison of adults with past to those with current PTSD showed persistence of SUD indicators. Conclusion: SUD prevalence increased substantially with trauma exposure even without PTSD and monotonically increased further with past and current PTSD, respectively, illustrating the differential effect of the clinical consequences of trauma.